{"pmid":32401361,"title":"Clinical Characteristics of Re-hospitalized Patients with COVID-19 in China.","text":["Clinical Characteristics of Re-hospitalized Patients with COVID-19 in China.","BACKGROUND: This study aims to observe the clinical characteristics of recovered patients from Coronavirus Disease 2019 (COVID 19) with positive in RT-PCR or serum antibody. METHODS: The profile, clinical symptoms, laboratory outcomes and radiologic assessments were extracted on 11 patients, who tested positive for COVID-19 with RT-PCR or serum antibody after discharged and was admitted to Hubei No. 3 People's Hospital of Jianghan University for a second treatment in March 2020. RESULTS: The average interval time between the first discharge and the second admission measured 16.00 +/- 7.14 days, ranging from 6 to 27 days. In the second hospitalization, 1 patient was positive for RT-PCR and serum antibody IgM-IgG, 5 patients were positive for both IgM and IgG but negative for RT-PCR. 3 patients were positive for both RT-PCR and IgG but negative for IgM. The main symptoms were cough (54.5%), fever (27.3%) and feeble (27.3%) in the second hospitalization. Compared with the first hospitalization, there were significant decreases in gastrointestinal symptoms (5 vs. 0, P=0.035), elevated levels of both white blood cell count(P=0.036) and lymphocyte count (P=0.002), remarkedly decreases in CRP and SAA (P<0.05) in the second hospitalization. Additionally, 6 patients' chest CT exhibited notable improvements in acute exudative lesions CONCLUSION: There could be the positive results for RT-PCR analysis or serum IgM-IgG in discharged patients, even with mild clinical symptoms, however, their laboratory outcomes and chest CT images would not indicate the on-going development in those patients. This article is protected by copyright. All rights reserved.","J Med Virol","Chen, Min","An, Wei","Xia, Fei","Yang, Ping","Li, Kuangyu","Zhou, Qin","Fang, Shasha","Liao, Yaling","Xu, Xin","Liu, Jialin","Liu, Shiguo","Qin, Tao","Zhang, Jianjun","Wei, Wei","Zhang, Yafang","Zhang, Guowei","Zhang, Mingwei","32401361"],"abstract":["BACKGROUND: This study aims to observe the clinical characteristics of recovered patients from Coronavirus Disease 2019 (COVID 19) with positive in RT-PCR or serum antibody. METHODS: The profile, clinical symptoms, laboratory outcomes and radiologic assessments were extracted on 11 patients, who tested positive for COVID-19 with RT-PCR or serum antibody after discharged and was admitted to Hubei No. 3 People's Hospital of Jianghan University for a second treatment in March 2020. RESULTS: The average interval time between the first discharge and the second admission measured 16.00 +/- 7.14 days, ranging from 6 to 27 days. In the second hospitalization, 1 patient was positive for RT-PCR and serum antibody IgM-IgG, 5 patients were positive for both IgM and IgG but negative for RT-PCR. 3 patients were positive for both RT-PCR and IgG but negative for IgM. The main symptoms were cough (54.5%), fever (27.3%) and feeble (27.3%) in the second hospitalization. Compared with the first hospitalization, there were significant decreases in gastrointestinal symptoms (5 vs. 0, P=0.035), elevated levels of both white blood cell count(P=0.036) and lymphocyte count (P=0.002), remarkedly decreases in CRP and SAA (P<0.05) in the second hospitalization. Additionally, 6 patients' chest CT exhibited notable improvements in acute exudative lesions CONCLUSION: There could be the positive results for RT-PCR analysis or serum IgM-IgG in discharged patients, even with mild clinical symptoms, however, their laboratory outcomes and chest CT images would not indicate the on-going development in those patients. This article is protected by copyright. All rights reserved."],"journal":"J Med Virol","authors":["Chen, Min","An, Wei","Xia, Fei","Yang, Ping","Li, Kuangyu","Zhou, Qin","Fang, Shasha","Liao, Yaling","Xu, Xin","Liu, Jialin","Liu, Shiguo","Qin, Tao","Zhang, Jianjun","Wei, Wei","Zhang, Yafang","Zhang, Guowei","Zhang, Mingwei"],"date":"2020-05-14T11:00:00Z","year":2020,"_id":"32401361","source":"PubMed","week":"202020|May 11 - May 17","doi":"10.1002/jmv.26002","keywords":["covid-19","clinical characteristics","convalescent patient"],"locations":["Hubei","China"],"countries":["China"],"countries_codes":["CHN|China"],"topics":["Diagnosis"],"weight":1,"_version_":1666714494861049856,"score":9.490897,"similar":[{"pmid":32458479,"title":"Diagnostic performance of immunochromatography assay for rapid detection of IgM and IgG in coronavirus disease 2019.","text":["Diagnostic performance of immunochromatography assay for rapid detection of IgM and IgG in coronavirus disease 2019.","Serologic assays have been developed to detect infection with coronavirus disease 2019 (COVID-19). This study was conducted to evaluate the diagnostic performance of an immunochromatography-based assay of human serum for COVID-19. The present study enrolled 149 subjects who had been tested by real-time reverse transcription-polymerase chain reaction (RT-PCR) for COVID-19 and were classified into two groups: 70 who were positive for COVID-19 and 79 who were negative for COVID-19 based on RT-PCR. An immunochromatography-based COVID-19 IgG/IgM rapid test on the sera of the study population was applied to measure the sensitivity, specificity, positive predictive value (PPV), negative predictive value (NPV), and receiver operating characteristic (ROC) curve compared to RT-PCR, with a 95% confidence interval (CI). IgM or IgG antibodies were detected in 65 subjects (92.9%) classified as positive for COVID-19 and in 3 subjects (3.8%) classified as negative for COVID-19. The sensitivity and specificity percentages for IgM or IgG antibodies were 92.9% (95% CI 84.1 - 97.6) and 96.2% (95% CI 89.3 - 99.2), respectively, with 95.6% PPV and 93.8% NPV. The PPV rapidly improved with increasing disease prevalence from 19.8% to 96.1% in the presence of either IgM or IgG, while the NPV remained high with a change from 99.9% to 93.1%. The area under the ROC curve was 0.945 (95% CI 0.903 - 0.988) for subjects with either IgM or IgG positivity. In conclusion, the immunochromatography-based COVID-19 IgG/IgM rapid test is a useful and practical diagnostic assay for detection of COVID-19, especially in the presence of IgM or IgG antibodies. This article is protected by copyright. All rights reserved.","J Med Virol","Choe, Jung-Yoon","Kim, Ji-Won","Kwon, Hyun Hee","Hong, Hyo-Lim","Jung, Chi Young","Jeon, Chang-Ho","Park, Eun-Jin","Kim, Seong-Kyu","32458479"],"abstract":["Serologic assays have been developed to detect infection with coronavirus disease 2019 (COVID-19). This study was conducted to evaluate the diagnostic performance of an immunochromatography-based assay of human serum for COVID-19. The present study enrolled 149 subjects who had been tested by real-time reverse transcription-polymerase chain reaction (RT-PCR) for COVID-19 and were classified into two groups: 70 who were positive for COVID-19 and 79 who were negative for COVID-19 based on RT-PCR. An immunochromatography-based COVID-19 IgG/IgM rapid test on the sera of the study population was applied to measure the sensitivity, specificity, positive predictive value (PPV), negative predictive value (NPV), and receiver operating characteristic (ROC) curve compared to RT-PCR, with a 95% confidence interval (CI). IgM or IgG antibodies were detected in 65 subjects (92.9%) classified as positive for COVID-19 and in 3 subjects (3.8%) classified as negative for COVID-19. The sensitivity and specificity percentages for IgM or IgG antibodies were 92.9% (95% CI 84.1 - 97.6) and 96.2% (95% CI 89.3 - 99.2), respectively, with 95.6% PPV and 93.8% NPV. The PPV rapidly improved with increasing disease prevalence from 19.8% to 96.1% in the presence of either IgM or IgG, while the NPV remained high with a change from 99.9% to 93.1%. The area under the ROC curve was 0.945 (95% CI 0.903 - 0.988) for subjects with either IgM or IgG positivity. In conclusion, the immunochromatography-based COVID-19 IgG/IgM rapid test is a useful and practical diagnostic assay for detection of COVID-19, especially in the presence of IgM or IgG antibodies. This article is protected by copyright. All rights reserved."],"journal":"J Med Virol","authors":["Choe, Jung-Yoon","Kim, Ji-Won","Kwon, Hyun Hee","Hong, Hyo-Lim","Jung, Chi Young","Jeon, Chang-Ho","Park, Eun-Jin","Kim, Seong-Kyu"],"date":"2020-05-28T11:00:00Z","year":2020,"_id":"32458479","source":"PubMed","week":"202022|May 25 - May 31","doi":"10.1002/jmv.26060","keywords":["covid-19","coronavirus","immunochromatography","real-time polymerase chain reaction"],"topics":["Diagnosis"],"weight":1,"_version_":1667967698871517184,"score":367.99533},{"pmid":32495914,"title":"No infectious risk of COVID-19 patients with long-term fecal 2019-nCoV nucleic acid positive.","text":["No infectious risk of COVID-19 patients with long-term fecal 2019-nCoV nucleic acid positive.","OBJECTIVE: It has recently been reported that some COVID-19 patients have long-term positive fecal nucleic acid after discharging from the hospital with negative nucleic acid in the respiratory tract, but it is unclear whether COVID-19 patients with positive long-term fecal nucleic acid tests have the risk of self-infection. PATIENTS AND METHODS: From January 25, 2020 to March 9, 2020, 5 COVID-19 patients with negative respiratory tract nucleic acid and positive fecal nucleic acid were observed and studied to explore whether these patients can re-infect themselves. Five patients with COVID-19 accompanied by diarrhea as the main gastrointestinal symptoms were carefully observed through clinical symptoms, imaging and other auxiliary examinations. The RT-PCR technology was used to continuously detect fecal and respiratory viral nucleic acids. The IgM antibody was detected on the 7th day of admission and IgM/IgG at the time of discharge. RESULTS: All 5 patients had symptoms of fever and diarrhea upon admission. The fecal nucleic acid was positive, as well as the throat swab was positive. All COVID-19 patients had positive IgM antibodies on the 7th day of admission and positive IgM and IgG at the time of discharge, and there were no abnormalities in the gastrointestinal examination on discharge. All 5 fecal nucleic acid tests were positive at the time of discharge. After continuous dynamic follow-up for 3-15 days, no clinical symptoms recurred, and the last nucleic acid test was negative. CONCLUSIONS: There is no risk of self-infection for COVID-19 patients with long-term 2019-nCoV nucleic acid positive in feces.","Eur Rev Med Pharmacol Sci","Wang, Q-X","Huang, K-C","Qi, L","Zeng, X-H","Zheng, S-L","32495914"],"abstract":["OBJECTIVE: It has recently been reported that some COVID-19 patients have long-term positive fecal nucleic acid after discharging from the hospital with negative nucleic acid in the respiratory tract, but it is unclear whether COVID-19 patients with positive long-term fecal nucleic acid tests have the risk of self-infection. PATIENTS AND METHODS: From January 25, 2020 to March 9, 2020, 5 COVID-19 patients with negative respiratory tract nucleic acid and positive fecal nucleic acid were observed and studied to explore whether these patients can re-infect themselves. Five patients with COVID-19 accompanied by diarrhea as the main gastrointestinal symptoms were carefully observed through clinical symptoms, imaging and other auxiliary examinations. The RT-PCR technology was used to continuously detect fecal and respiratory viral nucleic acids. The IgM antibody was detected on the 7th day of admission and IgM/IgG at the time of discharge. RESULTS: All 5 patients had symptoms of fever and diarrhea upon admission. The fecal nucleic acid was positive, as well as the throat swab was positive. All COVID-19 patients had positive IgM antibodies on the 7th day of admission and positive IgM and IgG at the time of discharge, and there were no abnormalities in the gastrointestinal examination on discharge. All 5 fecal nucleic acid tests were positive at the time of discharge. After continuous dynamic follow-up for 3-15 days, no clinical symptoms recurred, and the last nucleic acid test was negative. CONCLUSIONS: There is no risk of self-infection for COVID-19 patients with long-term 2019-nCoV nucleic acid positive in feces."],"journal":"Eur Rev Med Pharmacol Sci","authors":["Wang, Q-X","Huang, K-C","Qi, L","Zeng, X-H","Zheng, S-L"],"date":"2020-06-05T11:00:00Z","year":2020,"_id":"32495914","source":"PubMed","week":"202023|Jun 01 - Jun 07","doi":"10.26355/eurrev_202005_21370","topics":["Diagnosis"],"weight":1,"_version_":1668712823959584769,"score":354.4147},{"pmid":32425648,"pmcid":"PMC7233230","title":"A preliminary study on serological assay for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in 238 admitted hospital patients.","text":["A preliminary study on serological assay for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in 238 admitted hospital patients.","In this study, we aimed to evaluate the diagnostic value of serological assay for SARS-CoV-2. A newly-developed ELISA assay for IgM and IgG antibodies against N protein of SARS-CoV-2 was used to screen the serums of 238 admitted hospital patients between February 6 and February 14, 2020 with confirmed or suspected SARS-CoV-2. SARS-CoV-2 RNA was detected on pharyngeal swab specimens using real time RT-PCR. 194 (81.5%) of the serums were detected to be antibody (IgM and/or IgG) positive, significantly higher than the positive rate of viral RNA (64.3%). There was no difference in the positive rate of antibodies between the confirmed patients (83.0%, 127/153) and the suspected patients (78.8%, 67/85), whose nucleic acid tests were negative. The antibody positive rates were very low in the first five days after initial onset of symptoms, and then rapidly increased as the disease progressed. After 10 days, the antibody positive rates jumped from below 50% to over 80%. However, the positive rates of viral RNA maintained above 60% in the first 11 days after initial onset of symptoms, and then rapidly decreased. Overall, the suspected patients were most likely infected by SARS-CoV-2. Before the 11th day after initial onset of symptoms, nucleic acid test is key for confirmation of viral infection. The combination of serological assay can greatly improve the diagnostic efficacy. After the 11th day post-disease onset, the diagnosis for viral infection should be majorly dependent on serological assay.","Microbes Infect","Liu, Lei","Liu, Wanbing","Zheng, Yaqiong","Jiang, Xiaojing","Kou, Guomei","Ding, Jinya","Wang, Qiongshu","Huang, Qianchuan","Ding, Yinjuan","Ni, Wenxu","Wu, Wanlei","Tang, Shi","Tan, Li","Hu, Zhenhong","Xu, Weitian","Zhang, Yong","Zhang, Bo","Tang, Zhongzhi","Zhang, Xinhua","Li, Honghua","Rao, Zhiguo","Jiang, Hui","Ren, Xingfeng","Wang, Shengdian","Zheng, Shangen","32425648"],"abstract":["In this study, we aimed to evaluate the diagnostic value of serological assay for SARS-CoV-2. A newly-developed ELISA assay for IgM and IgG antibodies against N protein of SARS-CoV-2 was used to screen the serums of 238 admitted hospital patients between February 6 and February 14, 2020 with confirmed or suspected SARS-CoV-2. SARS-CoV-2 RNA was detected on pharyngeal swab specimens using real time RT-PCR. 194 (81.5%) of the serums were detected to be antibody (IgM and/or IgG) positive, significantly higher than the positive rate of viral RNA (64.3%). There was no difference in the positive rate of antibodies between the confirmed patients (83.0%, 127/153) and the suspected patients (78.8%, 67/85), whose nucleic acid tests were negative. The antibody positive rates were very low in the first five days after initial onset of symptoms, and then rapidly increased as the disease progressed. After 10 days, the antibody positive rates jumped from below 50% to over 80%. However, the positive rates of viral RNA maintained above 60% in the first 11 days after initial onset of symptoms, and then rapidly decreased. Overall, the suspected patients were most likely infected by SARS-CoV-2. Before the 11th day after initial onset of symptoms, nucleic acid test is key for confirmation of viral infection. The combination of serological assay can greatly improve the diagnostic efficacy. After the 11th day post-disease onset, the diagnosis for viral infection should be majorly dependent on serological assay."],"journal":"Microbes Infect","authors":["Liu, Lei","Liu, Wanbing","Zheng, Yaqiong","Jiang, Xiaojing","Kou, Guomei","Ding, Jinya","Wang, Qiongshu","Huang, Qianchuan","Ding, Yinjuan","Ni, Wenxu","Wu, Wanlei","Tang, Shi","Tan, Li","Hu, Zhenhong","Xu, Weitian","Zhang, Yong","Zhang, Bo","Tang, Zhongzhi","Zhang, Xinhua","Li, Honghua","Rao, Zhiguo","Jiang, Hui","Ren, Xingfeng","Wang, Shengdian","Zheng, Shangen"],"date":"2020-05-20T11:00:00Z","year":2020,"_id":"32425648","source":"PubMed","week":"202021|May 18 - May 24","doi":"10.1016/j.micinf.2020.05.008","keywords":["sars-cov-2","diagnosis","nucleic acid test","serological assay"],"topics":["Diagnosis"],"weight":1,"_version_":1667252837954879488,"score":349.3469},{"pmid":32350462,"title":"Antibody responses to SARS-CoV-2 in patients with COVID-19.","text":["Antibody responses to SARS-CoV-2 in patients with COVID-19.","We report acute antibody responses to SARS-CoV-2 in 285 patients with COVID-19. Within 19 days after symptom onset, 100% of patients tested positive for antiviral immunoglobulin-G (IgG). Seroconversion for IgG and IgM occurred simultaneously or sequentially. Both IgG and IgM titers plateaued within 6 days after seroconversion. Serological testing may be helpful for the diagnosis of suspected patients with negative RT-PCR results and for the identification of asymptomatic infections.","Nat Med","Long, Quan-Xin","Liu, Bai-Zhong","Deng, Hai-Jun","Wu, Gui-Cheng","Deng, Kun","Chen, Yao-Kai","Liao, Pu","Qiu, Jing-Fu","Lin, Yong","Cai, Xue-Fei","Wang, De-Qiang","Hu, Yuan","Ren, Ji-Hua","Tang, Ni","Xu, Yin-Yin","Yu, Li-Hua","Mo, Zhan","Gong, Fang","Zhang, Xiao-Li","Tian, Wen-Guang","Hu, Li","Zhang, Xian-Xiang","Xiang, Jiang-Lin","Du, Hong-Xin","Liu, Hua-Wen","Lang, Chun-Hui","Luo, Xiao-He","Wu, Shao-Bo","Cui, Xiao-Ping","Zhou, Zheng","Zhu, Man-Man","Wang, Jing","Xue, Cheng-Jun","Li, Xiao-Feng","Wang, Li","Li, Zhi-Jie","Wang, Kun","Niu, Chang-Chun","Yang, Qing-Jun","Tang, Xiao-Jun","Zhang, Yong","Liu, Xia-Mao","Li, Jin-Jing","Zhang, De-Chun","Zhang, Fan","Liu, Ping","Yuan, Jun","Li, Qin","Hu, Jie-Li","Chen, Juan","Huang, Ai-Long","32350462"],"abstract":["We report acute antibody responses to SARS-CoV-2 in 285 patients with COVID-19. Within 19 days after symptom onset, 100% of patients tested positive for antiviral immunoglobulin-G (IgG). Seroconversion for IgG and IgM occurred simultaneously or sequentially. Both IgG and IgM titers plateaued within 6 days after seroconversion. Serological testing may be helpful for the diagnosis of suspected patients with negative RT-PCR results and for the identification of asymptomatic infections."],"journal":"Nat Med","authors":["Long, Quan-Xin","Liu, Bai-Zhong","Deng, Hai-Jun","Wu, Gui-Cheng","Deng, Kun","Chen, Yao-Kai","Liao, Pu","Qiu, Jing-Fu","Lin, Yong","Cai, Xue-Fei","Wang, De-Qiang","Hu, Yuan","Ren, Ji-Hua","Tang, Ni","Xu, Yin-Yin","Yu, Li-Hua","Mo, Zhan","Gong, Fang","Zhang, Xiao-Li","Tian, Wen-Guang","Hu, Li","Zhang, Xian-Xiang","Xiang, Jiang-Lin","Du, Hong-Xin","Liu, Hua-Wen","Lang, Chun-Hui","Luo, Xiao-He","Wu, Shao-Bo","Cui, Xiao-Ping","Zhou, Zheng","Zhu, Man-Man","Wang, Jing","Xue, Cheng-Jun","Li, Xiao-Feng","Wang, Li","Li, Zhi-Jie","Wang, Kun","Niu, Chang-Chun","Yang, Qing-Jun","Tang, Xiao-Jun","Zhang, Yong","Liu, Xia-Mao","Li, Jin-Jing","Zhang, De-Chun","Zhang, Fan","Liu, Ping","Yuan, Jun","Li, Qin","Hu, Jie-Li","Chen, Juan","Huang, Ai-Long"],"date":"2020-05-01T11:00:00Z","year":2020,"_id":"32350462","source":"PubMed","week":"202018|Apr 27 - May 03","doi":"10.1038/s41591-020-0897-1","topics":["Diagnosis"],"weight":1,"_version_":1666138495590072322,"score":341.70435},{"pmid":32387968,"title":"Clinical evaluation of an immunochromatographic IgM/IgG antibody assay and chest computed tomography for the diagnosis of COVID-19.","text":["Clinical evaluation of an immunochromatographic IgM/IgG antibody assay and chest computed tomography for the diagnosis of COVID-19.","BACKGROUND: We evaluated the clinical performance of an immunochromatographic (IC) IgM/IgG antibody assay for severe acute respiratory syndrome coronavirus 2 (SARS-CoV2) and chest computed tomography (CT) for the diagnosis of Coronavirus disease 2019 (COVID-19). METHODS: We examined 139 serum specimens collected from 112 patients with COVID-19 and 48 serum specimens collected from 48 non-COVID-19 patients. The presence of IgM/IgG antibody for SARS-COV2 was determined using the One Step Novel Coronavirus (COVID-19) IgM/IgG Antibody Test. Chest CT was performed in COVID-19 patients on admission. FINDINGS: Of the139 COVID-19 serum specimens, IgM was detected in 27.8 %, 48.0 %, and 95.8 % of the specimens collected within 1 week, 1-2 weeks, and >2 weeks after symptom onset and IgG was detected in 3.3 %, 8.0 %, and 62.5 %, respectively. Among the 48 non-COVID-19 serum specimens, 1 generated a false-positive result for IgM. Thirty-eight of the 112 COVID-19 patients were asymptomatic, of whom 15 were positive for IgM, and 74 were symptomatic, of whom 22 were positive for IgM and 7 were positive for IgG. The diagnostic sensitivity of CT scan alone and in combination with the IC assay was 57.9 % (22/38) and 68.4 % (26/38) for the asymptomatic patients and 74.3 % (55/74) and 82.4 % (61/74) for the symptomatic patients, respectively. CONCLUSION: The IC assay had low sensitivity during the early phase of infection, and thus IC assay alone is not recommended for initial diagnostic testing for COVID-19. If RT-qPCR is not available, the combination of chest CT and IC assay may be useful for diagnosing COVID-19.","J Clin Virol","Imai, Kazuo","Tabata, Sakiko","Ikeda, Mayu","Noguchi, Sakiko","Kitagawa, Yutaro","Matuoka, Masaru","Miyoshi, Kazuyasu","Tarumoto, Norihito","Sakai, Jun","Ito, Toshimitsu","Maesaki, Shigefumi","Tamura, Kaku","Maeda, Takuya","32387968"],"abstract":["BACKGROUND: We evaluated the clinical performance of an immunochromatographic (IC) IgM/IgG antibody assay for severe acute respiratory syndrome coronavirus 2 (SARS-CoV2) and chest computed tomography (CT) for the diagnosis of Coronavirus disease 2019 (COVID-19). METHODS: We examined 139 serum specimens collected from 112 patients with COVID-19 and 48 serum specimens collected from 48 non-COVID-19 patients. The presence of IgM/IgG antibody for SARS-COV2 was determined using the One Step Novel Coronavirus (COVID-19) IgM/IgG Antibody Test. Chest CT was performed in COVID-19 patients on admission. FINDINGS: Of the139 COVID-19 serum specimens, IgM was detected in 27.8 %, 48.0 %, and 95.8 % of the specimens collected within 1 week, 1-2 weeks, and >2 weeks after symptom onset and IgG was detected in 3.3 %, 8.0 %, and 62.5 %, respectively. Among the 48 non-COVID-19 serum specimens, 1 generated a false-positive result for IgM. Thirty-eight of the 112 COVID-19 patients were asymptomatic, of whom 15 were positive for IgM, and 74 were symptomatic, of whom 22 were positive for IgM and 7 were positive for IgG. The diagnostic sensitivity of CT scan alone and in combination with the IC assay was 57.9 % (22/38) and 68.4 % (26/38) for the asymptomatic patients and 74.3 % (55/74) and 82.4 % (61/74) for the symptomatic patients, respectively. CONCLUSION: The IC assay had low sensitivity during the early phase of infection, and thus IC assay alone is not recommended for initial diagnostic testing for COVID-19. If RT-qPCR is not available, the combination of chest CT and IC assay may be useful for diagnosing COVID-19."],"journal":"J Clin Virol","authors":["Imai, Kazuo","Tabata, Sakiko","Ikeda, Mayu","Noguchi, Sakiko","Kitagawa, Yutaro","Matuoka, Masaru","Miyoshi, Kazuyasu","Tarumoto, Norihito","Sakai, Jun","Ito, Toshimitsu","Maesaki, Shigefumi","Tamura, Kaku","Maeda, Takuya"],"date":"2020-05-11T11:00:00Z","year":2020,"_id":"32387968","source":"PubMed","week":"202020|May 11 - May 17","doi":"10.1016/j.jcv.2020.104393","keywords":["covid-19","chest ct scan","immunochromatographic assay","sars-cov-2"],"topics":["Diagnosis"],"weight":1,"_version_":1666428892589588482,"score":324.06384}]}